EGRX - イ―グル・ファ―マシュ―ティカルズ （Eagle Pharmaceuticals Inc.）

-- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens.

Eagle Pharmaceuticals (EGRX) said it had reached a settlement agreement with Dr

https://www.investing.com/news/assorted/eagle-pharmaceuticals-reaches-settlement-with-dr-reddys-laboratories-on-bendeka-432SI-3049393

WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “Dr. Reddy’s”). Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Click here to find out why EGRX stock is a Hold.

Eagle Pharma (EGRX) announced its preliminary guidance for 2023 on Tuesday, indicating $4.20-$4.53 of adjusted non-GAAP earnings per share in line with consensus. Read the full story here.

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference as follows:

-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma -- WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE)

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Eagle Pharmaceuticals (EGRX) and Enalare Therapeutics'' ENA-001 to treat Apnea of Prematurity (AoP).AoP…

Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (BARDA). In partnership with BARDA, ENA-001 is being developed in an intramuscular (IM) formulation for potential use in patients experiencing community drug overdose and as a potential … Full story available on Benzinga.com

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.95% to the previous day’s close as strong demand from buyers drove the stock to $28.93. Actively observing the price movement in the last trading, the stock closed the session at $30.12, falling within a range of $27.91 … Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Is An Exciting Stock To Watch. Read More »

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20 th Annual Global Healthcare Conference as follows:

Endo International''s Par Pharmaceutical Inc on Wednesday failed to persuade a U.S. appeals court to revive its lawsuit seeking to block Eagle Pharmaceuticals Inc from selling a generic version of Par''s best-selling blood-pressure drug Vasostrict.